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In the present study, we investigated the relationshipbetween polymorphismsin the estrogen-metabolizing genesCYP17, CYP1B1,
CYP1A1, and COMT and genomic instability in the peripheral blood lymphocytes of 62 BC patients and 62 controls considering
that increased or prolonged exposure to estrogen can damage the DNA molecule and increase the genomic instability process in
breast tissue. Our data demonstrated increased genomic instability in BC patients and that individuals with higher frequencies of
MN exhibited higher risk to BC when belonging Val/Metgenotype of the COMT gene. We also observed that CYP17 and CYP1A1
polymorphisms can modify the risk to BC depending on the menopause status. We can conclude that the genetic background in
estrogen metabolism pathway can modulate chromosome damage in healthy controls and patients and thereby inﬂuence the risk
to BC. These ﬁndings suggest the importance to ally biomarkers of susceptibility and eﬀects to estimate risk groups.
1.Introduction
Breast cancer (BC) is a prevalent cancer among women
worldwide, and it has been estimated that there are 71 cases
of BC per year for every 100000 women in Brazil. BC shows
some distinctive features concerning age-speciﬁc incidence
rates [1]. It is one of the most common causes of death
among women, and epidemiologicalstudies indicate that the
age of onset is slowly, but steadily, becoming lower. This
suggests that there may be changes in environmental factors
that are aﬀecting BC risk [2].
The risk factors for BC include early age of menarche,
delayed menopause, contraceptive use, hormonal replace-
ment therapy, above-average body mass index, exposure to
environmental pollutants, smoking, and alcohol use [1–3].
However, it is generally believed that the initiation of BC is
a consequence of cumulative genetic damage, which leads
to genetic alterations that result in the activation of proto-
oncogenes and the inactivation of tumor suppressor genes
[4]. A large number of genetic variants that are associated
with BC risk have been identiﬁed in genes involved in a wide
variety of functions, including steroid hormone metabolism,
detoxiﬁcation of environmental carcinogens, DNA damage
repair, and tumor suppression [5].
As observed in drug and chemical metabolism, there
is considerable interindividual variability (i.e., polymor-
phisms) in the conjugation pathways of both estrogen
and catechol estrogens. These person-to-person diﬀerences,2 Journal of Biomedicine and Biotechnology
Table 1: Characteristics of breast cancer patients and controls.
Patients N (%) Controls N (%) P
Smoking
Yes 14 (22.5) 22 (35.4) .1
No 48 (77.5) 40 (64.6)
Menopause status
Post 32 (51.6) 23 (37) .1
Pre 30 (48.4) 39 (63)
HRT
Yes 20 (32.2) 28 (45.1) .2
No 42 (67.8) 34 (54.9)
Full-term pregnancy
Yes 44 (70.9) 42 (68.4) .8
No 18 (29.1) 20 (32.2)
HRT: hormone replacement therapy.
which are attributed to polymorphisms in the genes encod-
ing for the respective enzymes, may deﬁne subpopulations
of women with higher lifetime exposure to hormone-
dependent growth promotion or to cellular damage from
particular estrogens and/or estrogen metabolites [4].
Current evidence suggests that the metabolic by-
products of estrogens in the body may act as initiators
of cellular alterations [6]. Estrogen metabolism products
such as quinone-catecholestrogen can bind to DNA and
form DNA adducts [7]. The generation of free radicals by
metabolic redox cycling between quinoneand hydroquinone
can damage DNA by causing strand breaks, 8-hydroxylation
of purines, and lipid hydroperoxide-mediated DNA modiﬁ-
cations [8].
Although still controversial, a number of genes involved
in biogenesis (CYP17), bioavailability (CYP1B1 and
CYP1A1),and degradation(COMT) ofestrogencompounds
contain polymorphisms that could aﬀect susceptibility to
BC [9]. They are called low penetrance genes (or sometimes
modiﬁer genes) and are, in this instance, deﬁned as genes
in which subtle sequence variations or polymorphisms may
be associated with a slightly to moderately increased relative
risk for BC [4].
The hypothesis of the present study is that polymorphic
variants of the estrogen metabolizing genes CYP17, CYP1B1,
CYP1A1, and COMT may aﬀect the spontaneous levels of
chromosome damage in lymphocytes of BC patients and
subsequently modulate BC risk.
Therefore, the objective of the present work was to
correlate the genotypes of polymorphic variants of the
above-mentioned genes with the basal levels of chromosome
damage inlymphocytesofuntreated BCpatientsand healthy
individuals. Micronucleus assay was employed to determine
the extent of baseline chromosome damage in BC patients
and controls, and PCR-RFLP was used for genotype analysis.
2.PatientsandMethods
2.1.Subjects. The BCpatientgroupconsistedof62untreated
women diagnosed with in situ or invasive ductal breast
carcinoma, ranging in age from 25 to 60 years old (mean
age, 50.5 years old) and free of any pathology associated with
the use of medication that is known to cause DNA damage.
The control group consisted of 62 women with ages ranging
from 25 to 50 years (mean age, 46.7-years old). They were
enrolled in the control group after a detailed investigation
in order to ensure that they were free from any breast
pathology. They came from the same geographical location,
their dietary habits were not appreciably diﬀerent, and they
were not occupationally exposed to genotoxic chemicals.
None of the subjects reported alcohol consumption, the use
of genotoxic medicine, presence of known inherited genetic
disorders or chronic diseases or exposure to ionizing or
nonionizing radiation, even for diagnostic or therapeutic
purposes, for at least one month prior to enrolling in the
study. Patients and controls enrolled in the present study did
not report family history of breast and/or ovarian cancer.
Characteristics of patients and controls are presented in
Table 1. This investigation was approved by the National
Ethics Committee (CONEP: 1217/2004) and was performed
in accordance with ethical standards. Informed consent of
patients and controls was obtained before inclusion in the
study and sample collection.
2.2. Blood Sampling. Samples of venous blood (10mL) were
collected in heparinized and EDTA Vacutainer tubes(Becton
Dickinson, NJ, USA) by venepuncture under sterile condi-
tions. The samples were coded, immediately protected from
direct light, and processed for genotyping and micronucleus
assay.
2.3. Genotype Determination. Genomic DNA samples were
obtained from blood lymphocytes using a Wizard Genomic
DNA Puriﬁcation Kit (Promega, Madison, WI). Isolated
DNA was resuspended in Tris-EDTA buﬀer (pH 8.0) and
stored at −20◦Cu n t i lu s e .
The T1931C polymorphism of the CYP17 gene was
determined by PCR-RFLP with the following primers:
sense, 5 -CAAGGTGAAGATCAGGGTAG-3  and antisense,
5 -GCTAGGGTAAGCAGCAAGAG-3 . The 145bp product
was digested overnight with 8 U of the restriction enzyme
MspA1I. The T allele remained intact, but the C allele
was digested into 75 and 70bp fragments. The V432L
polymorphism of the CYP1B1 gene was genotyped with the
following primers: sense, 5 -TCACTTGCTTTTCTCTCTCC-
3  and antisense, 5 -AATTTCAGCTTGCCTCTTG-3 .T h e
650bp product was digested overnight with 8U of the
restriction enzyme AcuI. The Leu allele was digested into 350
and 300bp fragments. The genotypes of the T3205C poly-
morphism ofthe CYP1A1geneweredeterminedwiththefol-
lowing primers: sense, 5 -TAGGAGTCTTGTCTCATGCCT-
3  and antisense, 5 -CAGTGAAGAGGTGTAGCCGCT-3 .
The 340bp PCR product was digested for 3h with 5U of
the restriction enzyme MspI. The C allele was digested into
200 and 140bp fragments, whereas the T allele remained
intact. The genotypes of the V158M polymorphism of
the gene COMT were determined with the following
primers: sense, 5 -TACTGTGGCTACTCAGCTGT-3  andJournal of Biomedicine and Biotechnology 3
Table 2: The genotype frequencies of the CYP17, CYP1B1, CYP1A1,a n dCOMT gene variants in breast cancer patients and controls, and
after menopause.
Genotype Breast cancer patients (n = 62) Controls (n = 62) OR (95% CI) P value
Number Frequency Number Frequency
CYP17
Premenopause
TT 16 0.25 22 0.35 1.0 (reference) .81
TC+CC 14 0.23 17 0.27 1.1 (0.4-2.9)
Postmenopause
TT 11 0.18 16 0.26 1.0 (reference) .01
TC+CC 21 0.34 7 0.12 4.3 (1.3–13.7)
CYP1B1
Premenopause
Val/Val 6 0.1 15 0.24 1.0 (reference) .11
Val/Leu+Leu/Leu 24 0.39 24 0.39 2.5 (0.8–7.5)
Postmenopause
Val/Val 11 0.18 6 0.1 1.0 (reference) .56
Val/Leu+Leu/Leu 21 0.33 17 0.27 0.6 (0.2–2.1)
CYP1A1
Premenopause
TT 16 0.25 36 0.58 1.0 (reference) .0004
TC+CC 14 0.23 3 0.05 10.5 (2.6–41.7)
Postmenopause
TT 24 0.39 17 0.27 1.0 (reference) 1.0
TC+CC 8 0.13 6 0.1 0.9 (0.2–3.2)
COMT
Premenopause
Val/Val 10 0.16 24 0.38 1.0 (reference) .02
Val/Met+Met/Met 20 0.32 15 0.24 3.2 (1.1–8.6)
Postmenopause
Val/Val 11 0.18 12 0.2 1.0 (reference) .2
Val/Met+Met/Met 21 0.34 11 0.18 2.0 (0.6–6.2)
Table 3: Frequency of micronucleated cells in untreated breast cancer women and controls with diﬀerent genotypes.
Genotype Breast cancer patients (n = 62) Controls (n = 62) P value
Number CBMN (‰) Number CBMN (‰)
CYP17
TT 27 19 ±8.93 8 9 .3 ±6.3 <.0001
TC+CC 35 18.2 ± 10.52 4 9 .6 ±5.4 <.0001
CYP1B1
Val/Val 17 18.7 ± 10.52 1 6 .7 ±4.1 <.0001
Val/Leu+Leu/Leu 45 18.5 ± 9.64 1 1 0 .3 ±5.9 <.0001
CYP1A1
TT 40 19.5 ± 10.25 3 9 .9 ±5.5 <.0001
TC+CC 22 16.7 ±99 9 .1 ±5.3 .001
COMT
Val/Val 21 15.2 ± 8.73 4 1 1 .3 ±6.7. 0 7
Val/Met+Met/Met 41 20.3 ±10 28 8.5 ±4.9 <.0001
MNF: micronucleusfrequency; M: mean; SE: standard error; patients compared to controls.4 Journal of Biomedicine and Biotechnology
Table 4: Estrogen-metabolizing gene polymorphisms in breast cancer patients and controls with frequency of micronucleated cells higher
than the mean of each group.
Genotype Breast cancer patients (n = 27) Controls (n = 26) OR (95% CI) P value
Number Frequency Number Frequency
CYP17
TT 12 0.44 9 0.35 1.0 (reference) .57
TC+CC 15 0.56 17 0.65 0.6 (0.2–2.0)
CYP1B1
Val/Val 6 0.22 3 0.12 1.0 (reference) .46
Val/Leu+Leu/Leu 21 0.78 23 0.88 0.46 (0.1–2.0)
CYP1A1
TT 21 0.78 16 0.62 1.0 (reference) .2
TC+CC 6 0.22 10 0.38 0.4 (0.1–1.5)
COMT
Val/Val 6 0.22 13 0.5 1.0 (reference) .04
Val/Met+Met/Met 21 0.78 13 0.5 3.5(1–11.4)↑
antisense, 5 -TGAAGCTGGTGTGAACACCT-3 . The 114bp
PCR productwas digested with 5U ofthe restriction enzyme
NlaIII. The Met allele was digested into fragments of 96,
54, 39, and 27bp, whereas the Val allele was digested into
fragments of 54 and 39bp only.
2.4. Cell Culture and Cytokinesis-Block Micronucleus Assay.
Lymphocyte cultures were prepared combining 0.5mL
of isolated lymphocytes in plasma with 5mL of com-
plete medium containing 78% of RPMI (Sigma-Aldrich
Co., USA), 20% inactivated fetal bovine serum (Gibco-
Invitrogen, Denmark), the antibiotics penicillin (5μg/mL,
Sigma-Aldrich Co., USA) and streptomycin (10μg/mL,
Sigma-AldrichCo., USA),and 2% phytohemagglutinin(Life
Technologies, Grand Island, NY, USA) to stimulate cell pro-
liferation. Cultures were incubated at 37◦C. After 44 hours
of incubation, cytochalasin B (Sigma-Aldrich Co., USA) was
added to the cultures to a ﬁnal concentration of 4μg/mL,
according to the method of Fenech and Morley [10]. One
thousand binucleated cells were analyzed per individual and
the frequency of binucleated cells micronucleated (BCMN)
wasdeterminedaccordingtothecriteria describedbyFenech
[11].
2.5. Statistical Analysis. The Mann-Whitney statistical test
was used to compare BCMN between patients and controls.
The frequency of BCMN in diﬀerent genotypes was analyzed
with one-way ANOVA and the statistical diﬀerences between
groups for BC risk was calculated using Fisher’s exact test
(two-tailed). Crude odds ratios (ORs) were calculated and
are given with 95% conﬁdence intervals (CIs). Results were
considered signiﬁcant when P<. 05.
3.Resultsand Discussion
Table 1 compares and shows the homogeneity of BC patients
and control groups according to their smoking habits,
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Figure 1:Frequency ofBCMNin untreated BCwomenandhealthy
controls.Atotalofonethousandbinucleated cells wereanalyzedfor
MN count in each of 62 BC patients and 62 age-matched controls.
Bars represent standard error of mean; ∗P<. 001 signiﬁcantly
diﬀerent from control group.
menopause status, hormone replacement therapy, and full-
term pregnancy. Basal level of chromosome damage was
measured by micronucleus (MN) assay in lymphocytes from
62 BC patients and 62 age-matched controls, as shown in
Figure 1. BC patients exhibited higher levels of chromosome
damage than controls according to BCMN (P<. 05).
Table 2 shows the genotype distributions in patients
and controls according to menopause status. The genotype
distributions for all cases were in agreement with those
predicted by the Hardy-Weinberg equilibrium. An asso-
ciation between BC occurrence and the C allele of the
T1931C polymorphism in the CYP17 gene was observed
in the postmenopause group (OR 4.3; 95% CI 1.3–13.7).
CYP1B1 V432L polymorphism had no association with BC
occurrence in pre- and postmenopause women, however, in
the premenopause women we observed increased risk to BC
when the C allele of CYP1A1 gene (T3205C polymorphism)
was present (OR 10.5; 95% CI 2.6–41.7). COMT Met allele
was also associated with BC occurrence in premenopause
women (OR 3.2; 95% CI 1.1–8.6).Journal of Biomedicine and Biotechnology 5
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Figure 2: Frequency of BCMN in untreated BC women and healthy controls considering the presence of estrogen-metabolizing genes
polymorphisms(a)CYP17,( b )CYP1B1,( c )CYP1A1,a n d( d )COMT. A total ofone thousandbinucleated cells were analyzedfor MN count
in each of 62 BC patients and 62 age-matched controls. Bars represent standard error of mean; ∗P<. 005 signiﬁcantly diﬀerent from the
wild type in the control group; #P<. 005 signiﬁcantly diﬀerent from the wild type in the patients group.
The basal levels of chromosome damage in BC patients
and controls among the diﬀerent genotypes are presented
in Table 3. BCMN frequencies were higher in BC than in
control group in all genotypes except for Val/Val of COMT
gene where diﬀerences between patients and controls were
not signiﬁcant (P = .07).
We also evaluated the inﬂuence of diﬀerent genotypes
considering the levels of chromosome damage in patient
and control groups individually (Figure 2). CYP17 T1931C
and CYP1A1 T3205C polymorphisms had no inﬂuence in
the frequency of BCMN in patients as well as in controls.
However, in control group, CYP1B1 432L allele was related
to increased frequencies of BCMN (P = .006). Diﬀerently,
patients with V158M polymorphism of COMT gene pre-
sented higher frequencies of BCMN when compared to the
wild-type counterparts (P = .04).
Finally, we tested the risk to BC in the group of patients
and controls that presented frequencies of BCMN higher
than the mean (higher than 18.5 BCMN for patients and
higher than 9.5 BCMN for controls) (Table 4). CYP17,
CYP1B1,a n dCYP1A1 polymorphisms did not modify the
occurrence of BC, however, COMT V158M polymorphism
was more frequent in BC than in control group and resulted
in signiﬁcant OR increasing (OR 3.5; 95% CI 1–11.4).
DNAdamagecanoccurspontaneouslyorasconsequence
of exposure to chemical or physical genotoxins. There are
modulators that can aﬀect the levels of spontaneous DNA
damage, including DNA repair genes, antioxidant defense
genes, and estrogen-metabolizing gene polymorphisms that
can lead to the accumulation of genotoxic estrogen sub-
products. High serum estrogen levels are thought to be
a major risk factor for BC [12]. In vitro and in vivo
animal and patient-based studies suggest that estrogens,
their metabolic compounds, and the entire biochemical
metabolic machinery may play a role in BC carcinogenesis
[13]. We can look forward into two diﬀerent processes by6 Journal of Biomedicine and Biotechnology
which hormones are related to BC: (i) one involves the
binding of estradiol to estrogen receptor (ER) alpha with the
stimulation of cell proliferation. Errors in DNA occurring
during replication result in ﬁxed mutations when not well
repaired; (ii) the other process results from the formation of
genotoxic metabolites of estradiol, which can bind to DNA,
cause depurination, and also result in mutations. Herein,
we focused on the second process. Therefore, in the present
study, the relationship between the SNPs in four estrogen-
metabolizing genes and basal levels of chromosome damage
was examined using lymphocytes of untreated BC women
andhealthycontrolsoncelymphocytescancirculateforyears
or evendecades, accumulating mutations in their DNA [14].
Results presented here show that the basal levels of
chromosome damage detected by MN assay and observed
in the control group are in accordance with those previously
reported in other control populations of similar age [15, 16].
It is well known that MN are formed by the condensation of
acentric chromosomal fragments or by whole chromosomes
lagging behind during cell division and that this is the only
biomarker that allows the evaluation of both clastogenic
and aneuploidogenic eﬀects in a vast range of cells, as they
are detected in interphase [17]. As we did not observe
any statistical diﬀerence between smoking and nonsmoking
patients or controls (data not shown), we grouped these
two subsets together for the analysis of the basal levels of
chromosome damage in patients and controls.
The investigation of basal levels of chromosome damage
in peripheral lymphocytes of untreated cancer subjects has
been previously reported. Baseline levels of DNA damage
were signiﬁcantly higher in bladder cancer patients than in
controls[18],andthef r equencyofMNins timulat edperiph-
eral blood cells from an untreated leukemia population was
signiﬁcantly greater than that in the control group [19].
Similar results were found by Lou et al. [14], who simul-
taneously investigated both baseline and ionizing radiation-
induced(IR)geneticdamageinperipherallymphocytesfrom
36 cancer patients using MN and comet assays. They found
thatbothspontaneousand IR-inducedgeneticdamages were
higher in patients than in controls.
In the present study, the primary objective was to
investigate the relationship between the genotypes of poly-
morphisms in estrogen-metabolizing genes and the extent
of endogenous chromosome damage. Although this is not
an epidemiological study, the odds ratio for the diﬀerent
genotypes was also examined and displayed interesting
ﬁndings.
The results presented here show that there is a slight sig-
niﬁcant relationship between the CYP17 polymorphism, and
BC risk is postmenopausal women, however, we found no
correlation between spontaneous chromosome damage and
the T1931C polymorphism of CYP17 gene, which encodes
for cytochrome p450C17α,a1 7 α-hydroxylase that catalyzes
the conversion ofpregnenolone and progesterone to 17-OH-
pregnenolone and 17-OH-progesterone, respectively [20].
Cytochrome p450C17α also has a 17,20-lyase activity that
converts hydroxylase products to dehydroepiandrosterone
(DHEAS) and androstenedione, respectively, which can be
further converted to estrogens and testosterone [20]. It
has been hypothesized that certain genotype variants in
the CYP17 gene result in higher hormone levels, leading
to an increased risk of BC. However, non-Hispanic white
women who were heterozygous or homozygous for the
variant allele of CYP17 had lower estrone, total testosterone,
free testosterone, and DHEAS concentrations compared to
women homozygous for the wild-type allele [21]. Chen and
Pei [22] applied both traditional meta-analysis and Bayesian
approach to determine the overall eﬀect of CYP17 T1931C
polymorphism on risk of BC and detected that carriers
of C allele were positively associated with risk of BC in
postmenopausal women and were inversely related to BC in
pre-menopausal women.
The V432L polymorphism of the CYP1B1 gene is located
within a catalytic heme-binding domain in exon 3 [23]a n d
hasbeen analyzed inseveralindependentstudiesthatpresent
controversial results. Chinese women with the Leu/Leu
genotype at the L432V polymorphism had a higher risk of
BC(OR=2.0,95%;CI =1.0–3.7)[24].Apositive association
wasalsoseeninTurkish womenbutwaslimitedtothosewith
ah i g hb o d ym a s si n d e x( O R= 2.3, 95%; CI = 1.3–4.2) [25].
In contrast, results presented here showed no association
between V432L polymorphism and BC occurrence in pre-
or postmenopause women (OR 2.5, 95% CI 0.8–7.5 and OR
0.6, 95% CI 0.2–2.1, resp.). A signiﬁcant inverse association
between the Val allele and BC risk was previously observed
in studies of African American or mixed populations [26].
It is interesting to note that in the control group, carriers
of the Leu allele exhibited higher levels of DNA damage
compared to homozygous wild-type individuals while this
was not observed in the patients group. We believe that this
diﬀerence between patients and controls is mostly due to
the increased spontaneous levels of chromosome damage in
BC which makes it diﬃcult to identify suitable diﬀerences in
BCMN between polymorphic and wild-type individuals. It
has been described that CYP1B1 catalyzes C4 hydroxylation
of estradiol (4-hydroxyestradiol (4-OHE2)). This metabo-
lite can undergo metabolic redox cycling to generate free
radicals such as superoxide and chemically reactive estrogen
semiquinone/quinone intermediates, which can form DNA
adducts [27, 28]. Anyway, these results suggest further
investigation of this polymorphism combined with other
low-penetrance gene polymorphisms such as DNA repair
in the modulation of spontaneous chromosome damage in
healthy women.
Cytochrome P450 1A1 (CYP1A1) is one of the most
important phase I enzymes expressed in breast tissue. It
catalyzes estrogen 2-hydroxylation, generating the 2-OH
estrogen metabolite, which can form DNA adducts [28, 29].
The 3205T→C polymorphism in CYP1A1 is located in
the 3  noncoding region and can aﬀect the modulation of
enzymatic activity and thereby the susceptibility risk to BC
[30].The results presentedhere showed that thefrequency of
this polymorphism was higher in premenopause BC women
than in controls and resulted in association to BC risk (OR
10.5, 95% CI 2.6–41.7), however, it had no eﬀect on the
frequency of BCMN in patients or in control group. The
rare CT and CC genotypes were detected in 14 patients
and three controls, and it, therefore, resulted in an extensiveJournal of Biomedicine and Biotechnology 7
conﬁdence interval (CI). Similar results were observed by
Taioli et al. [30] that demonstrated an association between
this polymorphism and BC cancer risk in African American
women (OR = 9.7 95%, CI 2.0–47.9), and Huang et
al. [31] demonstrated the same association in Taiwanese
women. Nevertheless, the association observed here must
be interpreted with caution considering the number of
individuals included in the present study and the fact that
C allele is rare.
The catechol-O-methyltransferase (COMT) catalyzes the
addition of a methyl group to reactive catechol estrogens,
converting them into stable methyloxyestrogen conjugates
[32]. In patients group, carriers of Met allele of the COMT
gene exhibited higher levels of chromosome damage relative
to those homozygous for the wild-type allele. Besides, when
the analysis considered the association of BC occurrence
in individuals that exhibited levels of chromosome damage
higherthanthemean, Metallele wasstrongly associated with
BC occurrence. This was an interesting ﬁnding especially
if we consider that biomarkers of susceptibility and risk
contribute to the identiﬁcation of high-risk subgroups of
the population, independent of whether they are associated
with previous exposure or they are involved in a deﬁned
pathway or mechanism [33]. It is known that G to A
polymorphism at codon 108 in the COMT gene leads to a
substitution of methionine to valine, resulting in decreased
enzymatic activity and increased thermolability [34, 35].
As metabolites of catechol estrogens have the potential to
induce oxidative DNA damage and form DNA adducts, the
conversion of catechol estrogens into stable conjugates may
be important in preventing BC [32]. In a previous study
of a Taiwanese population, a strong association between the
COMT polymorphism and BC risk was observed (OR = 3.5
95%, CI 1.15–13.3) [31].
The correlation between genetic polymorphisms and
speciﬁc phenotypes was evaluated by Synowiec et al. [36].
They correlated a polymorphism in a DNA repair gene
with oxidative DNA damage in 41 BC patients and 48
controls. They demonstrated a strong association between
BC occurrence and the C/C genotype of the RAD51-
135G/C polymorphism, the Ser/Ser genotype of the OGG1-
Ser326Cys polymorphism and the Lys/Gln genotype of
the XPD-Lys751Gln polymorphism. In contrast, the G/C
genotypeoftheRAD-135G/CpolymorphismandtheLys/Lys
genotype of the XPD-Lys751Gln polymorphism exhibited a
protective eﬀect against BC. In this study, the risk of BC was
calculated in patients and controls that had higher levels of
endogenous oxidative DNA damage.
We previously reported that Brazilian untreated BC
patients exhibited higher levels of chromosome damage than
healthy controls [37]a n dt h a tXRCC3 polymorphism was
weakly associated with the risk to BC in those individuals
that presented higher levels of chromosome damage [38]. It
is well known that DNA damage as detected in peripheral
blood represents a surrogate for what would be observed
in breast tissue. While the polymorphisms are obviously
expressed in both breast tissue and lymphocytes, the level
of expression of the genes and in particular, the level of
substrate that in our present hypothesis is estradiol, may
be and is likely very diﬀerent within breast tissue and the
lymphocytes, however, genome damage in lymphocytes may
be correlated with cancer-initiating events in target tissues
via a common genetic, dietary, or environmental factor [39].
Therefore, the manifestation of eﬀectsof the polymorphisms
on levels of the reactive quinones may be quite diﬀerent
in breast tissue and lymphocytes, making extrapolation of
the ﬁndings being reported to implications for BC quite
tenuous. As mentioned above, this is not an epidemiological
study and although the limited number of participants, we
consider that our results point that polymorphisms in the
enzymes involved in the metabolism of estradiol/estrone to
reactive quinones that cause DNA damage may represent
low penetrance risk factors susceptible of further detailed
investigations.
4.Conclusions
It is unknown whether the healthy controls and patients with
BChadequallevelsofDNAdamagebeforetheappearance of
clinical symptoms in the patients. It is also unclear whether
MN enhancement is a consequence or causative agent of the
disease process [19]. However, the followup of those controls
who are carriers of Met allele of CYP1B1 gene that exhibited
higher frequencies of BNMN than wild-type counterparts
could help to further answer this question.
In conclusion, according to the data presented here
both the genetic background of genes involved estrogen
metabolism and DNA damage in healthy controls and
patients can modulate BC risk reﬂected by higher chromo-
somal damage in lymphocytes.
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